30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
Lipid-lowering medications (LLMs) and especially statin drugs can delay cognitive decline and dementia onset in individuals with and without mild cognitive impairment (MCI) at baseline. 4 key findings →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Cross-sectional epidemiological and clinical research suggests that lower cardiac index is associated with abnormal brain aging, including smaller brain volumes, increased white matter hyperintensities, and worse cognitive performances. 4 key findings →
Design: cross-sectional Participants: 184 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We aimed to verify the association between diabetes and the risk of dementia, Alzheimer's disease, and vascular dementia in twins and to explore whether genetic and early-life environmental factors could contribute to this association. 4 key findings →
Design: case-control study Participants: 13,693 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Sample 1 included 1656 participants (mean [range] age, 58.1 [29.7-85.6] years; 903 female [54.5%]), and sample 2 included 935 participants (mean [range] age, 67.6 [60.0-85.6] years; 518 female [55.4%]). 4 key findings →
Design: cohort study Participants: 1,656 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of the 14 685 participants (7355 female [50%] and 7330 male [50%]; mean [SD] age, 73.8 [8.5] years) who met the inclusion criteria, 221 participants (1.5%) developed LOE during follow-up. 5 key findings →
Design: longitudinal study Participants: 713 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
After a median follow-up time of 14.3 (7.9-20.0) years, dementia was recorded in 530 (1.2%) individuals with type 1 diabetes and 1,867 (0.9%) age-, sex-, and county-matched control individuals (mean baseline age 33.0 [14.0] years). 4 key findings →
Design: cohort study Participants: 43,440 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Over a mean follow-up of 7.9 years, 694 incident dementia cases occurred. 5 key findings →
Design: cohort study Participants: 82,391 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The 4417 participants in the study included 2618 women (59%) and had a mean (SD) age of 71.3 (4.7) years. 5 key findings →
Design: cross-sectional Participants: 2,618 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Worldwide, the prevalence of dementia is increasing and diet as a modifiable factor could play a role. 3 key findings →
Participants: 493,888 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
At baseline, 4,463 subjects were without dementia, 836 of whom had HL. 3 key findings →
Design: cohort study Participants: 4,463 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These results confirm the absence of a neurocognitive risk associated with statin treatment and suggest a potential favourable role of statins. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
After adjusting for various risk factors, participants with low socioeconomic status (vs high) had increased risk for early-onset dementia (3·38, 2·61-4·37), and overall lifestyle mediated 3·2% (1·8-5·7) of the association. 4 key findings →
Design: cohort study Participants: 345 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Growing evidence suggests that fine particulate matter (PM 2.5 ) likely increases the risks of dementia, yet little is known about the relative contributions of different constituents. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The demographic and health transitions will lead to large and rapid increases in the numbers of dependent older people particularly in middle income countries (MIC). 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Recent studies suggest that delirium is associated with risk of dementia and also acceleration of decline in existing dementia. 5 key findings →
Participants: 232 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
While dementia affects 6-10% of persons 65 years or older, industrialized countries have witnessed an alarming rise in obesity. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Persistent pain was associated with accelerated memory decline and increased probability of dementia. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
To assess age-, sex-, and subtype-specific incidence rates of dementia and to calculate the risk of dementia, the authors performed a large, community-based, prospective cohort study on dementia as part of the Rotterdam Study. 4 key findings →
Design: cohort study Participants: 7,046 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Rotterdam Study previously found that higher dietary intakes of vitamins E and C related to lower risk of dementia and Alzheimer disease (AD) over 6 years of follow-up. 4 key findings →
Design: cohort study Participants: 5,395 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Sex differences in major cardiovascular risk factors for incident (fatal or non-fatal) all-cause dementia were assessed in the UK Biobank. 4 key findings →
Participants: 502,226 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Low hemoglobin and anemia are associated with cognitive impairment and Alzheimer's disease (AD). 4 key findings →
Design: longitudinal study Participants: 6,833 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Advanced glycation end products (AGEs) and their receptor (RAGE) are implicated in the pathophysiological processes of dementia and potentially underlie the association of diabetes with neurodegeneration. 4 key findings →
Design: cohort study Participants: 1,021 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In addition, the underlying mechanism and driven mediators are largely unknown. 4 key findings →
Design: cohort study Participants: 154,549 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cognitive decline is a leading cause of disability and death in old age but its neurobiological bases are not well understood. 4 key findings →
Design: cohort study Participants: 130 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 20 relevant studies involving 44,893 individuals were included in the analysis. 5 key findings →
Design: systematic review Participants: 42,955 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events